Glaxo delay gives Wellcome chance
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Analysts believe Wellcome's chances of fighting off the hostile £9bn-plus takeover bid from Glaxo by finding an alternative white knight bidder have received a boost from the predator's delay in posting its official offer document.
It looks increasingly possible Wellcome will have up to five weeks to find its preferred suitor, as brokers and sources close to both companies believe Glaxo will not post its formal offer document before it publishes interim trading results next week. They have been brought forward from 16 February.
"It obviously makes sense to do the offer document and results in tandem," a Glaxo source said.
Wellcome's main shareholder, Wellcome Trust, has said it will review its decision to commit irrevocably its 39.5 per cent stake to Glaxo if a higher bid emerges within 21 days of the offer document being published.
An industry source said: "Any delay in posting the Glaxo offer document obviously benefits Wellcome, as the clock doesn't start ticking on the 21-day time limit until then. It will be difficult to put an alternative higher bid together, and Wellcome willwelcome any extra space they can get."
The City sees only half a dozen potential alternative bidders: Merck, Johnson & Johnson, Bristol Myers Squibb and Pfizer in the US; Roche, the Swiss group, and Bayer, the German pharmaceuticals giant.
Only a few of the top companies could afford to pay a higher price without rationalisation on the scale planned by Glaxo, which Wellcome found unpalatable, one analyst said.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments